アダリムマブ (遺伝子組換え) (JAN);
アダリムマブ (遺伝子組換え) [アダリムマブ後続1] (JAN);
アダリムマブ (遺伝子組換え) [アダリムマブ後続2] (JAN);
アダリムマブ (遺伝子組換え) [アダリムマブ後続3] (JAN);
アダリムマブ (遺伝子組換え) [アダリムマブ後続4] (JAN);
Adalimumab (USAN/INN);
Adalimumab (genetical recombination) (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 2] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 3] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 4] (JAN);
Adalimumab-adaz;
Adalimumab-adbm;
Adalimumab-afzb;
Adalimumab-atto;
Adalimumab-bwwd;
Adalimumab-fkjp;
Adalimumab-aaty;
Adalimumab-aacf;
Adalimumab-aqvh;
Adalimumab-ryvk

ABRILADA (Pfizer Laboratories Div Pfizer), ABRILADA (Pfizer Laboratories Div Pfizer), ADALIMUMAB (Biocon Biologics), ADALIMUMAB (CELLTRION USA), ADALIMUMAB (Golden State Medical Supply), ADALIMUMAB (Mylan Specialty L.P.), ADALIMUMAB (Sandoz), ADALIMUMAB-AACF (Fresenius Kabi USA), ADALIMUMAB-ADBM (Boehringer Ingelheim Pharmaceuticals), ADALIMUMAB-ADBM (QUALLENT PHARMACEUTICALS HEALTH LLC), ADALIMUMAB-RYVK (Quallent Pharmaceuticals Health LLC), AMJEVITA (A-S Medication Solutions), AMJEVITA (A-S Medication Solutions), AMJEVITA (Amgen USA), AMJEVITA (Amgen), CYLTEZO (Boehringer Ingelheim Pharmaceuticals), HADLIMA (A-S Medication Solutions), HADLIMA (A-S Medication Solutions), HADLIMA (A-S Medication Solutions), HADLIMA (A-S Medication Solutions), HADLIMA (Organon LLC), HULIO (Biocon Biologics), HULIO (Mylan Specialty L.P.), HUMIRA (A-S Medication Solutions), HUMIRA (AbbVie), HUMIRA (Cordavis Limited), HYRIMOZ (Cordavis Limited), HYRIMOZ (Sandoz), IDACIO (Fresenius Kabi USA), SIMLANDI (Teva Pharmaceuticals USA), YUFLYMA (CELLTRION USA), YUSIMRY (Coherus BioSciences)

(Heavy chain)
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSA ITWNSGHIDY
ADSVEGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAKVS YLSTASSLDY WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD
ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQGIR NYLAWYQQKP GKAPKLLIYA ASTLQSGVPS
RFSGSGSGTD FTLTISSLQP EDVATYYCQR YNRAPYTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H148-H204, H224-L214, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'96, H'148-H'204, H'224-L'214, H'265-H'325, H'371-H'429, L23-L88, L134-L194, L'23-L'88, L'134-L'194)

抗炎症薬, 抗リウマチ薬, 抗TNFα抗体

希少疾病用医薬品指定: 壊疽性膿皮症

TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]

DDI search